𝔖 Bobbio Scriptorium

✦ LIBER ✦

120 High pathological complete response rate of neo-adjuvant combination of docetaxel, carboplatin and trastuzumab in patients with HER2-overexpressing breast cancer: preliminary results

✍ Scribed by K.R. Zeynalova; Y.V. Vishnevskaya; I.P. Ganshina

Book ID: 119601137
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 62 KB
Volume: 8
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(10)70151-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical trial of liposomal-enca

Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study

✍ Anton, A.; Ruiz, A.; Segui, M. A.; Calvo, L.; Munoz, M.; Lao, J.; Sancho, F.; Fe 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 82 KB

439 Significantly Higher Pathologic Comp

439 Significantly Higher Pathologic Complete Response Rate with Weekly Compared with Three-weekly Paclitaxel and Carboplatin Plus Trastuzumab Neoadjuvant Therapy – Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-positive Breast Cancer

✍ Z.M. Shao; C.M. Chen; Y. Zhou; S. Chen; Y.F. Hou; G.Y. Liu; G.H. Di; J.S. Lu; J. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB